A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
What is the purpose of this trial?
This phase II trial studies how well atezolizumab works in treating patients with alveolar soft part sarcoma that has not been treated, has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as atezolizumab, may allow the immune system cells to find and kill the tumor cells.
- Ages18 years and older
- Trial withNational Cancer Institute (NCI)
- Start Date06/10/2022
- End Date10/31/2020
- Last Updated06/12/2022
- Study HIC#2000021392